Login
$SPRB
$42.25 -$1.06 (2.45%) Live

$SPRB 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Biologics License Application (“BLA”) Submission for Tralesinidase Alfa Enzyme Replacement Therapy (“TA-ERT”) for the Treatment of MPS IIIB Remains on Track for December 2026 Amended Avenue Loan Agreement to Increase Tranche 2 Availabili...

12 Aug 2026 8-K: Results of Operations and Financial Condition

Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected to Initiate in the Fou...

27 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 27, 2026, Spruce Biosciences, Inc. (the “Company”) appointed Adrian Quartel, M.D., FFPM, as the Company’s Chief Medical Officer, replacing Dr. Kirk Ways, who had been serving as the Company’s Interim Chief Medical Officer. Dr. Wa...

26 May 2026 8-K: Submission of Matters to a Vote of Security Holders

Spruce Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026, in a virtual format. As of March 24, 2026, the record date for the Annual Meeting, there were 1,372,278 shares ...

13 May 2026 8-K: Results of Operations and Financial Condition

Long-Term TA-ERT Data Presented at the 22nd Annual WORLDSymposium™ Highlight Rapid and Durable Reduction of Heparan Sulfate and Stabilization of Cognitive Function in Patients with MPS IIIB

22 Apr 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to Purchase up to 50,000 Shares of Common Stock

20 Mar 2026 8-K: Termination of a Material Definitive Agreement

Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026

09 Mar 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a...

05 Feb 2026 8-K: Regulation FD Disclosure; Other Events

Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

08 Jan 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a...

15 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 11, 2025, the board of directors (the “Board”) of Spruce Biosciences, Inc. (the “Company”) appointed Keli Walbert to the Board, effective immediately. Ms. Walbert will serve as a Class I Director, with an initial term expirin...

12 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 11, 2025, Tiba Aynechi, Ph.D. notified Spruce Biosciences, Inc. (the “Company”) of her resignation as a member of the board of directors (the “Board”) of the Company and as the Chair of the Compensation Committee of the Board...

10 Nov 2025 8-K: Results of Operations and Financial Condition

Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB)

17 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On October 15, 2025, Bali Muralidhar, Ph.D. notified Spruce Biosciences, Inc. (the “Company”) of his resignation as a member of the Company’s board of directors (the “Board”) and as a member of the compensation committee of the Board, ef...

08 Oct 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October 7, 2025, is made by and among SPRUCE BIOSCIENCES, INC., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their...

14 Aug 2025 8-K: Results of Operations and Financial Condition

Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

24 Jul 2025 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more

Spruce’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 5, 2025

12 Jun 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events

To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01.

29 May 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +4 more

This Purchase Agreement (this “Agreement”) is made as of May 28, 2025, by and between the purchaser listed on Exhibit A attached hereto (the “Purchaser”) and Spruce Biosciences, Inc., a Delaware corporation (the “Company”).

06 May 2025 8-K: Results of Operations and Financial Condition

Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support